Insight

2018 Health Care & Life Sciences Investment Outlook

Healthcare and life sciences will face continued disruption in 2018 as new technologies, economic pressures and consumer/patient demands change the industry.

KPMG and Leavitt Partners surveyed 265 corporate finance professionals about their thoughts about the industry and 12 separate sub-sectors. While some fear a market bubble from the lofty valuations seen in some transactions, many see continued growth, investment and merger activity. Beyond the survey results, the 2018 Healthcare and Life Sciences Investment Summary looks at healthcare policy and key disrupters that are reshaping more than one-sixth of the U.S. economy.

2018 Health Care & Life Sciences Investment Outlook

The 2018 Healthcare and Life Sciences Investment Summary looks at healthcare policy and key disrupters that are reshaping more than one-sixth of the U.S. economy.

Related content

Our practice

KPMG can help healthcare and life sciences organizations solve their toughest business challenges.